Open Access223 VERSICAN IS A PROMISING CANDIDATE BIOMARKER IN THE COMBINATION OF DOCETAXEL WITH THALIDOMIDE AS SECOND LINE CHEMOTHERAPY IN CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL RESISTANCE
Author(s) -
Hiroaki Shiina,
Hiroaki Yasumoto,
Miho Hiraki,
Naoko Arichi,
Yozo Mitsui,
Takeo Hiraoka,
Masahiro Sumura,
Satoshi Honda,
Mikio Igawa
Publication year - 2012
Publication title -
the journal of urology
Language(s) - English
Resource type - Journals
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1016/j.juro.2012.02.277
Subject(s) - docetaxel , medicine , prostate cancer , oncology , chemotherapy , cancer , gynecology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom